-

Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research

Three Labs in Japan and Spain to Receive Novel Compact Ascend Evo 1.0 GHz Magnets

UTRECHT, The Netherlands--(BUSINESS WIRE)--At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories. The new Ascend Evo 1.0 GHz NMR magnet, operating at 4.2 Kelvin, allows functional structural biology and clinical phenomics researchers to dive deeper into the structural details, binding and dynamics of molecular structures and complexes for fundamental cell biology and pathobiology research. It complements Bruker’s Avance Neo 1.1 GHz and 1.2 GHz NMR systems with two-story 2 Kelvin magnets, which typically are used at shared national NMR facilities, such as the 1.2 GHz NMR at the Dutch Ultra-high Field Magnetic Resonance Consortium, operating at Utrecht University.

A first new 1.0 GHz NMR order comes from the RIKEN Center for Biosystems Dynamics Research in Yokohama, Japan. The RIKEN team under Dr. Ichio Shimada will use GHz NMR to study dynamical structures of biomolecules in solution and to investigate the relationships between dynamical structures and biological function or pathobiology.

Bruker also confirms two 1.0 GHz NMR orders from major research centers and universities in Bilbao and Barcelona, both in Spain, for clinical and biological research:

Professor Óscar Millet, Principal Investigator of the Precision Medicine and Metabolism Lab at CIC bioGUNE stated: “The Ascend Evo 1.0 GHz will advance our research in clinical metabolomics. This novel magnet provides highest-resolution NMR to investigate the molecular patterns and mechanism of action of prevalent and rare diseases in precision medicine, all in a single-story lab and with a smaller footprint.”

Professor Miquel Pons Valles, Group Leader of the BioNMR Group at Universitat de Barcelona and his team use biophysical methods, especially NMR, as well as chemical biology, molecular biology, and computations to study proteins in regulatory processes, where dynamics is essential for function. The Ascend Evo 1.0 GHz will also advance their research on intrinsically disordered proteins (IDPs).

The recently introduced, compact Ascend Evo 1.0 GHz NMR magnet has significantly reduced footprint, weight, and ceiling height requirements to fit into most single-story laboratories. Along with a 65% reduction in helium consumption, this provides more structural biology principal investigators, individual universities and research centers, as well as advanced biopharma companies access to the sensitivity and resolution of GHz NMR in order to enable new research capabilities.

Another innovation is Bruker’s new Heliosmart Recovery, a compact and easy-to-site system that collects helium boil-off from NMR magnets. Helium gas is stored in high-pressure cylinders, which can be used by cryogen suppliers for reliquification. The Heliosmart Recovery system can collect the steady-state boil-off of several NMR magnets in parallel with typical recovery rates of 80% – 85%.

Dr. Falko Busse, President of the Bruker BioSpin Group, commented: "We are excited to announce the three new GHz orders, which will incorporate our innovative, single-story Ascend Evo 1.0 GHz magnet. This technological marvel brings the power of GHz NMR to more laboratories due to its smaller footprint, reduced maintenance requirements and lower Helium consumption.”

Please join Bruker at Euromar at our booth for interaction with our NMR and EPR teams.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investors:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 7243 769 5500
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags

Contacts

Investors:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 7243 769 5500
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026

SAN DIEGO--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. At AACR 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx...

Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w...

Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati...
Back to Newsroom